$VBIV plenty of cash to wait for proper offer from BP. By 7/1/22: - Prehevbrio market traction immediately upon receiving ACIP recommendation - 2900 updates - 1901 registration trials (phase 2, 2/3) initiated Plenty of serious value drivers that must play out before reasonable valuation is discussed, IMO. It seems Merck willing to low-ball but pay nice premium when PoC has been established…so anticipate them paying up after the above play out, unless someone swoops in prior with a ballsy premium biopharmadive.com/news/merc...
9
9 Likes